Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Diclofenac-Based OTC Drugs Recommended for Approval
March 16, 2009
- FDA to Require New Clinical Data on Alogliptin: Takeda
March 16, 2009
- Pro-Online Sale Parties Exchange Opinions
March 16, 2009
- Clozaril Recommended for Approval under Strict Monitoring System
March 16, 2009
- Acquisition of Wyeth to Make Pfizer No. 1 in Japan: Mr Iwasaki
March 16, 2009
- Mr Toda Warns Consumers against Counterfeit Drugs Sold Via Internet
March 16, 2009
- Shasun to Enhance Its Presence in Japan via Its Subsidiary in Tokyo
March 16, 2009
- Guidance on Biosimilars Issued by Korosho
March 16, 2009
- Chuikyo Subcommittee Discusses Pros and Cons of "Generics Coefficient"
March 16, 2009
- Council Proposes Nat'l Project to Quickly Develop Unapproved Drugs
March 16, 2009
- Amended Hypertension Management GL Discussed at JHF Workshop
March 16, 2009
- 3 More National Medical Centers Publish Lists of Generics They Use
March 16, 2009
- Nippon Shinyaku Licenses Prulifloxacin to Lee's Pharma in China
March 16, 2009
- Studies on Ethnic Differences between Japan, China and South Korea Progress
March 16, 2009
- Teijin, Nissan Chemical License NTC-801 to BMS
March 16, 2009
- Cancer Treatment Using Unapproved Peptide Vaccine Applied for as Advanced Medical Technology
March 16, 2009
- Bristol-Myers to Promote Sprycel with Over 200 MRs
March 16, 2009
- More Objective Endpoints Needed for Allergic Rhinitis Treatments
March 16, 2009
- 2008 Ethical Drug Market in Japan Totaled ¥8,254.3 Bil. on NHI Price Basis: IMS
March 16, 2009
- R&D NEWS IN BRIEF
March 16, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…